CxxC domain for isolation and determination of methylation status of CpG islands

submit enquiry

University: University of Edinburgh

Sector(s): Life Sciences, Healthcare & Pharmaceuticals

About Opportunity:

The current method employed to analyse CGI methylation are cumbersome, time-consuming, use toxic reagents, and can damage template DNA. Given the importance of CGI methylation in influencing the expression of genes, a new method is required for faster analysis free of DNA damaging chemicals.


Using the CxxC domain, which specifically binds non-methylated CGIs, in a column format, it is possible to generate a complete library of non-methylated CGIs from tissues or cells of interest. Complete isolation of all CGIs is facilitated through the combined use of CxxC and MBD domains, the latter binding specifically to methylated CGIs. Isolation of CGIs using CxxC domain followed by downstream array- or PCR-based analysis allows fast and accurate identification of non-methylated CGIs from the sample of interest. This method has successfully been applied to various human tissues, available as an array of non-methylated CGIs. The CxxC domain column provides a >50-fold enrichment of non-methylated CGIs from bulk DNA, validating the use of this domain.

Key Benefits:

  • No need of toxic chemicals that damage DNA samples
  • Reduced assay time and costs
  • Simple, efficient, and reproducible two-step process


  • Research reagents
  • Diagnostic and prognostic tool
  • Comparative analysis of methylation status in disease and non-diseased tissues

IP Status:

Patent on CxxC domain, CGI library, and CxxC domain based reagents has been granted in USA, UK, and EU


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Lab in a Pill

    Scientists at the University of Glasgow have pioneered a new sensor technology, Lab-in-a-Pill, that could have major impact on the cost and effectiveness of bowel cancer treatment.

    Expires: Created:
  • Thermoelectric Sensor

    The Thermoelectric Sensor technology is a Nano-Calorimetric Sensor which measures very small changes in temperature. The IP provides a route to making the most sensitive calorimetric measurements (with a resolution of 0.1 mK).

    Expires: Created:
  • Parkinson's Disease Model

    The University of Glasgow is offering an exciting new model for the evaluation of new treatments for Parkinsons disease

    Expires: Created:
  • Combination Treatment for MRSA Nasal Carriage and MRSA-infected Wounds

    The new treatment is a combination of a peptide (ranalexin) with bacteria cell wall-digesting protein (lysostaphin), which specifically targets and kills Staphylococcus aureus, including MRSA.

    Expires: Created:
  • Synergistic antifungal combination

    Candida species are a major cause of catheter-related nosocomial bloodstream infections. We have identified that the combination of an echinocandin antifungal with certain antimicrobial peptides results in potent, synergistic inhibition of yeast pathogens in vitro, so offering a potential combinatio...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.